6-Dimethylamino-purin | 23687-23-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 6-Dimethylamino-purin
• 英文别名: dimethyl-(7(9)H-purin-8-yl)-amine；N,N-dimethyl-7H-purin-8-amine
• CAS: 23687-23-2
• 化学式: C₇H₉N₅
• 分子量: 163.182
• InChiKey: WNLBOWJFJNZYPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel phosphonate derivatives of certain nucleosides
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0477454A1

  公开（公告）日：1992-04-01

  This invention relates to novel phosphonate derivatives of certain nucleoside analogs, to the methods for their preparation and to their use as anti-viral agents.

  这项发明涉及某些核苷类似物的新磷酸酯衍生物，涉及它们的制备方法以及它们作为抗病毒药物的用途。
• [EN] 14-MEMBERED MACROLIDES DERIVED FROM LEUCOMYCINS<br/>[FR] MACROLIDES A 14 ELEMENTS ISSUS DE LEUCOMYCINES
  申请人：ENANTA PHARM INC

  公开号：WO2002060912A1

  公开（公告）日：2002-08-08

  Novel 14-Membered Macrolides derived from Leucomycins comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and processes for the preparation of such compounds.

  由Leucomycins衍生的14元大环内酯类小分子化合物，与药学上可接受的载体组合成治疗有效量的药物组合物，用于治疗细菌感染的方法是向哺乳动物施用包含治疗有效量的该化合物的制药组合物，并且还包括制备这种化合物的工艺。
• Novel fluorophosphonate nucleotide derivatives
  申请人：MERRELL PHARMACEUTICALS INC.

  公开号：EP0335770A2

  公开（公告）日：1989-10-04

  This invention relates to fluoromethylphosphonate derivatives of certain nucleosides, to methods for their preparation and to their use as antiviral and antitumoral agents.

  本发明涉及某些核苷的氟甲基膦酸盐衍生物、其制备方法及其作为抗病毒剂和抗肿瘤剂的用途。
• Mononucleotide analogues and intermediates therefor
  申请人：CIBA-GEIGY AG

  公开号：EP0614906A1

  公开（公告）日：1994-09-14

  A compound of formula where R¹ is hydrogen or a protecting group Q; R² is hydrogen, a C₁-C₈ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₃-C₈ cycloaliphatic radical, a C₇-C₁₃ araliphatic radical, an alkali metal ion or an ammonium ion; R³ and R⁴ are independently hydrogen, halogen or hydroxy; R⁵ is C₆-C₁₀ aryloxythiocarbonyloxy, the C₆-C₁₀ aryl group being unsubstituted or substituted, or R⁵a; R⁵a is hydrogen, fluorine, chlorine, hydroxy, -OR⁸, -OCOR⁸ or silyloxy substituted by three C₁-C₁₅ hydrocarbyl groups; R⁶ is hydrogen, a C₁-C₁₀ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₁₆ araliphatic radical, -COR⁹, -SO₂R⁹ or silyl substituted by three C₁-C₁₅ hydrocarbyl groups; R⁷ is a monovalent nucleoside base radical, hydroxyl, -OR⁸ or -OCOR⁸, and and R⁹ are independently a C₁-C₁₀ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a C₆-C₁₅ aromatic radical or a C₇-C₁₆ araliphatic radical; or R⁵ and the indicated R⁶O-together denote an isopropylidenedioxy group or R⁵ and R⁷ together denote an isopropylidenedioxy group, provided that when R⁵ and R⁷ together denote isopropylidenedioxy, R¹ R², R³ R⁴ and R⁶ are not all hydrogen.

  式中的化合物 式中 R¹ 是氢或保护基 Q； R² 是氢、C₁-C₈ 脂肪族基、C₆-C₁₅ 芳族基、C₃-C₈ 环脂族基、C₇-C₁₃ 芳族基、碱金属离子或铵离子； R³ 和 R⁴ 独立地为氢、卤素或羟基； R⁵ 是 C₆-C₁₀芳氧基硫代羰氧基，C₆-C₁₀ 芳基是未取代的或取代的，或 R⁵a； R⁵a 是氢、氟、氯、羟基、-OR⁸、-OCOR⁸ 或被三个 C₁-C₁₅烃基取代的硅氧基； R⁶ 是氢、C₁-C₁₀ 脂肪族基、C₆-C₁₅ 芳族基、C₇-C₁₆ 脂肪芳族基、-COR⁹、-SO₂R⁹ 或被三个 C₁-C₁₅ 烃基取代的硅氧基； R⁷ 是一价核苷碱基、羟基、-OR⁸ 或 -OCOR⁸，以及 R⁹ 独立地是 C₁-C₁₀ 脂肪族基、C₃-C₈ 环脂肪族基、C₆-C₁₅ 芳族基或 C₇-C₁₆ 脂肪族基；或 R⁵ 和 R⁶O 共同表示异亚丙基二氧基，或 R⁵ 和 R⁷ 共同表示异亚丙基二氧基，但当 R⁵ 和 R⁷ 共同表示异亚丙基二氧基时，R¹ R²、R³ R⁴ 和 R⁶ 并非都是氢。
• Dinucleotide and oligonucleotide analogues
  申请人：CIBA-GEIGY AG

  公开号：EP0614907A1

  公开（公告）日：1994-09-14

  A dinucleotide analogue of formula where B¹ and B² are each independently a monovalent nucleoside base radical; R¹ is R¹a or Z; R¹a, R², R³ and R⁴ are each independently hydrogen, halogen or hydroxy; R⁵ is R⁵a or Z; R⁶ is hydrogen or R⁶a; R⁷ is hydrogen, alkyl-N,N-dialkylphosphoramidyl or R⁷a, R⁸ is R⁸a or Z, or the indicated R⁷O and R⁸ together denote an isopropylidenedioxy group; R⁵a and R⁸a are each independently hydrogen, halogen, hydroxy, -OR¹⁰, -OCOR¹⁰ or silyloxy substituted by three C₁-C₁₅ hydrocarbyl groups; R⁶a and R⁷a are each independently a C₁-C₁₀ aliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₃₀ araliphatic radical, -COR¹¹, -SO₂R¹¹ or silyl substituted by three C₁-C₁₅ hydrocarbyl groups; R⁹ is hydrogen, a C₁-C₈ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a C₆-C₁₅ aromatic radical, a C₇-C₁₃ araliphatic radical, an alkali metal ion or an ammonium ion; R¹⁰ and R¹¹ are each independently a C₁-C₁₀ aliphatic radical, a C₃-C₈ cycloaliphatic radical, a C₆-C₁₅ aromatic radical or a C₇-C₁₆ araliphatic radical; Rx and Ry are independently hydrogen, halogen, hydroxy, a C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₈ cycloalkyl, C₆-C₁₅ aryl, C₇-C₁₆ aralkyl, C₁-C₁₀ alkoxy, C₂-C₁₀ alkenoxy, C₆-C₁₀ aryloxy or C₇-C₁₆ aralkyloxy group, which is substituted or unsubstituted, or -OCORz; Rz is a substituted or unsubstituted C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₃-C₈ cycloalkyl, C₆-C₁₅ aryl or C₇-C₁₆ aralkyl group; and Z is C₆-C₁₀ aryloxythiocarbonyloxy, the C₆-C₁₀ aryl group being substituted or unsubstituted.

  式中的二核苷酸类似物 其中 B¹ 和 B² 各自独立地为一价核苷碱基； R¹ 是 R¹a 或 Z； R¹a、R²、R³ 和 R⁴ 各自独立地为氢、卤素或羟基； R⁵ 是 R⁵a 或 Z； R⁶ 是氢或 R⁶a R⁷ 是氢、烷基-N,N-二烷基磷酰胺或 R⁷a，R⁸ 是 R⁸a 或 Z，或 R⁷O 和 R⁸ 共同表示异亚丙基二氧基； R⁵a和R⁸a各自独立地是氢、卤素、羟基、-OR¹⁰、-OCOR¹⁰或被三个C₁-C₁₅烃基取代的硅氧基； R⁶a和R⁷a各自独立地是C₁-C₁₀脂肪族基、C₆-C₁₅芳香族基、C₇-C₃₀脂肪族基、-COR¹¹、-SO₂R¹¹或被三个C₁-C₁₅烃基取代的硅烷基； R𠞙 是氢、C₁-C₈ 脂肪族基、C₃-C₈ 环脂肪族基、C₆-C₁₅ 芳族基、C₇-C₁₃ 芳族基、碱金属离子或铵离子； R¹⁰ 和 R¹¹ 各自独立地为 C₁-C₁₀ 脂肪族基、C₃-C₈ 环脂肪族基、C₆-C₁₅ 芳族基或 C₇-C₁₆ 脂肪族基； Rx 和 Ry 独立地为氢、卤素、羟基、C₁-C₁₀ 烷基、C₂-C₁₀ 烯基、C₃-C₈ 环烷基、C₆-C₁₅ 芳基、C₇-C₁₆ 芳烷基、C₁-C₁₀ 烷氧基、C₂-C₁₀ 烯氧基、C₆-C₁₀ 芳氧基或 C₇-C₁₆ aralkyloxy 基团，这些基团被取代或未被取代，或 -OCORz； Rz 是取代或未取代的 C₁-C₁₀ 烷基、C₂-C₁₀ 烯基、C₃-C₈ 环烷基、C₆-C₁₅ 芳基或 C₇-C₁₆ 芳烷基；和 Z 是 C₆-C₁₀ 芳氧基硫代羰氧基，C₆-C₁₀ 芳基可被取代或未被取代。